Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor [Phase 2]
Phase 2 trial evaluating a PRAME-targeted immunotherapy for non-small cell lung cancer after tumor removal.
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA [Phase 2]
Phase 2 trial update evaluating olmutinib in T790M-positive non-small cell lung cancer detected via liquid biopsy in BALF extracellular vesi…
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression [Phase 1]
Phase 1 study of ADCT-502 in HER2-expressing advanced solid tumors including breast cancer and non-small cell lung cancer has terminated wit…
-
CLINICAL_TRIALS trial_result · 2019-08-26Clinical Trial Update: Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study [Phase 3]
Phase 3 study comparing pembrolizumab to platinum-based chemotherapy in PD-L1–positive advanced/metastatic non-small cell lung cancer (China…
-
CLINICAL_TRIALS trial_result · 2019-08-21Clinical Trial Update: Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M [Phase 2]
A Phase 2 clinical trial evaluating the combination of Anlotinib with Osimertinib as second-line therapy for stage IIIb-IV non-small cell lu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-08-21Clinical Trial Update: Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation [Phase 2]
Phase 2 study investigating Pyrotinib in previously treated non-small cell lung cancer with EGFR or ERBB2 exon 20 insertion mutations.
-
CLINICAL_TRIALS trial_result · 2019-08-15Clinical Trial Update: A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy [Phase 3]
Phase 3 trial evaluating icotinib alone vs icotinib with radiation therapy for brain metastases in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2019-08-15Clinical Trial Update: Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC) [Phase 2]
Phase 2 clinical trial update evaluating TQ-B3101 for ROS1-positive non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2019-08-12Clinical Trial Update: Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation [Phase 3]
Phase 3 trial update of afatinib in advanced non-small cell lung cancer with EGFR mutation completed; results posted.
-
CLINICAL_TRIALS trial_result · 2019-08-08Clinical Trial Update: Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. [Phase 3]
A Phase 3 clinical trial evaluated erlotinib and docetaxel in non-small cell lung cancer patients stratified by VeriStrat status; results co…
-
CLINICAL_TRIALS trial_result · 2019-08-07Clinical Trial Update: Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases [Phase 2]
Phase 2 trial update evaluating risk-adapted SABR for Stage I non-small cell lung cancer and lung metastases.
-
CLINICAL_TRIALS trial_result · 2019-08-05Clinical Trial Update: Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) [Phase 1]
Phase 1 study evaluating nivolumab in combination with various chemotherapies or as monotherapy for advanced non-small cell lung cancer; tri…
-
CLINICAL_TRIALS trial_result · 2019-08-05Clinical Trial Update: Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial investigating Erlotinib or Crizotinib in combination with chemoradiation for Stage III non-small cell lung cancer; study termi…
-
CLINICAL_TRIALS trial_result · 2019-08-02Clinical Trial Update: Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer [Phase 2]
Phase 2 trial update evaluating gefitinib, AZD9291, or selumetinib plus docetaxel, or an initial immune-mediated therapy with a sequential s…
-
CLINICAL_TRIALS trial_result · 2019-08-01Clinical Trial Update: Palliative Thoracic Radiotherapy Plus BKM120 [Phase 1]
Phase 1 trial evaluating palliative thoracic radiotherapy combined with BKM120 in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2019-07-30Clinical Trial Update: A Phase I/II Trial of Stereotactic Body Radiation Therapy [Phase 1, Phase 2]
Phase I/II trial evaluating stereotactic body radiation therapy for inoperable stage I/II non-small cell lung cancer completed with results …
-
CLINICAL_TRIALS trial_result · 2019-07-23Clinical Trial Update: TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy [Phase 3]
Phase 3 open-label trial evaluating rociletinib versus single-agent cytotoxic chemotherapy in EGFR-mutant NSCLC after prior EGFR-TKI and pla…
-
CLINICAL_TRIALS trial_result · 2019-07-23Clinical Trial Update: A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 1, Phase 2]
A phase 1/2 trial evaluating daratumumab in combination with atezolizumab versus atezolizumab alone in previously treated advanced or metast…
-
CLINICAL_TRIALS trial_result · 2019-07-11Clinical Trial Update: A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial comparing Alectinib with Crizotinib and assessing pharmacokinetics in Asian participants with treatment-naive ALK-positive adv…
-
CLINICAL_TRIALS trial_result · 2019-07-11Clinical Trial Update: A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial comparing alectinib to crizotinib in treatment-naive ALK-positive advanced non-small cell lung cancer completed with results p…
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients [Phase 3]
Phase 3 trial comparing icotinib to first-line chemotherapy with maintenance in EGFR-positive lung adenocarcinoma; completed study.
-
CLINICAL_TRIALS trial_result · 2019-07-05Clinical Trial Update: A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC [Phase 1, Phase 2]
Phase 1b/2 study investigating rociletinib in combination with MPDL3280A in advanced/metastatic EGFR-mutant non-small cell lung cancer was t…
-
CLINICAL_TRIALS trial_result · 2019-07-01Clinical Trial Update: Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients [Phase 1]
Phase 1 trial update on crizotinib plus pembrolizumab in ALK-positive advanced non-small cell lung cancer; study terminated with results pos…
-
CLINICAL_TRIALS trial_result · 2019-06-24Clinical Trial Update: Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer [Phase 2]
A Phase 2 trial comparing IV topotecan/docetaxel combination vs docetaxel alone as second-line therapy in advanced non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2019-06-20Clinical Trial Update: Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations. [Phase 3]
A Phase 3 clinical trial evaluating a combination therapy of Ectiecinib, Pemetrexed, and Platinum in metastatic non-squamous non-small cell …